65069-54-7

Basic information

• Product Name: Thiourea, [4-(methylthio)phenyl]-
• CAS NO: 65069-54-7
• Molecular Formula: C8H10N2S2
• Molecular Weight: 198.313
• Mol File: 65069-54-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Thiourea, [4-(methylthio)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Thiourea, [4-(methylthio)phenyl]-(65069-54-7)
• EPA Substance Registry System: Thiourea, [4-(methylthio)phenyl]-(65069-54-7)

Safety Data

• Hazardous Substances Data: 65069-54-7(Hazardous Substances Data)

Upstream product

• 1147550-11-5 ammonium thiocyanate 
• 104-96-1 4-methylsulfanylaniline 
• 65069-50-3 N-[(4-methylsulfanylphenyl)carbamothioyl]benzamide 

Downstream Products

• 100061-45-8 (4-methylsulfanyl-phenyl)-(4-methyl-thiazol-2-yl)-amine 
• 65069-81-0 2-Methyl-1-(4-methylsulfanyl-phenyl)-isothiourea; hydriodide 
• 17557-67-4 2-amino-6-(methylsulfonyl)benzothiazole 
• 65070-17-9 N-(4-Methylsulfanyl-phenyl)-morpholine-4-carboxamidine; hydriodide 
• 50850-92-5 2-amino-6-methylthiobenzothiazole 

Relevant articles and documents

Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors

Sphingosine kinases (SphK1, SphK2) are main regulators of sphingosine-1-phosphate (S1P), which is a pleiotropic lipid mediator involved in numerous physiological and pathophysiological functions. SphKs are targets for novel anti-cancer and anti-inflammatory agents that can promote cell apoptosis and modulate autoimmune diseases. Herein, we describe the design, synthesis and evaluation of an aminothiazole class of SphK inhibitors. Potent inhibitors have been discovered through a series of modifications using the known SKI-II scaffold to define structure-activity relationships. We identified N-(4-methylthiazol-2-yl)-(2,4′-bithiazol)-2′-amine (24, ST-1803; IC50values: 7.3 μM (SphK1), 6.5 μM (SphK2)) as a promising candidate for further in vivo investigations and structural development.

Nitrogen heterocyclic carboximidamide compounds

5-, 6- or 7-Membered fully saturated 1-azacarbocyclic-2-ylidene derivatives of guanidine having anti-secretory and hypoglycemic activities, and further useful for treatment of cardiovascular disease states.